Why the study?
Does losartan improve haemodynamic parameters in patients with heart failure?
Does losartan improve haemodynamic parameters in patients with heart failure?
Losartan demonstrates favorable acute and chronic hemodynamic effects in patients with heart failure, supporting its potential therapeutic role.
Answers are grounded in this paper and cite their sources.
Losartan may improve hemodynamics in HF; leaves open whether benefits extend to clinical outcomes in randomized trials.
BACKGROUND: Losartan is a novel, orally active, non-peptide angiotensin II receptor antagonist which specifically blocks the angiotensin II (AT1) receptor. It is postulated that losartan will have beneficial haemodynamic effects in heart failure similar to angiotensin converting enzyme inhibitors. RECENT FINDINGS: In patients with heart failure a single dose of losartan resulted in increased angiotensin II and decreased aldosterone levels. Systemic vascular resistance and systemic blood pressure were reduced. A 12-week study in similar patients found a persisting effect on systemic vascular resistance and systemic blood pressure after 12 weeks. Pulmonary capillary wedge pressure and heart rate were reduced and cardiac index increased after 12 weeks despite little acute effect on these parameters. CONCLUSIONS: Losartan resulted in favourable and persisting haemodynamic effects in patients with heart failure. Further studies will be required to fully define the role of this drug in heart failure.
No takes yet. Share an insight, caveat, or question.
Crozier et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: